Fairfield, CT - (July 21, 2010) - Competitive Technologies, Inc. (NYSE Amex: CTT) today announced that the NYSE Amex (the Exchange) has postponed indefinitely the delisting hearing it had scheduled for July 22, 2010, pending review of the final completion of CTT's sale of two million shares of CTT common stock to Crisnic Fund. The fund raise will provide CTT capital to increase shareholder equity required to retain the Exchange listing, and to more aggressively sell its non-invasive Calmare® Pain Therapy Treatment device. The transaction is currently being funded following the July 14, 2010, date that the SEC declared the required registration statement effective, and CTT anticipates that the final closing of the fund raise will occur shortly.

"We have worked hard to meet the Exchange's standards and will continue to work to maximize shareholder value as we increase sales of our non-invasive Calmare Pain Therapy Treatment medical device," said John B. Nano, CTT's Chairman, President, and CEO.

"Calmare pain therapy is the only highly effective treatment for chemotherapy-induced peripheral neuropathy (CIPN) without the harmful, adverse side effects of narcotic pain killers," Mr. Nano continued. "From the growing body of evidence-based patient outcomes we know that in addition to CIPN, our Calmare device successfully treats chronic neuropathic and oncologic pain resulting from cancer, phantom limb syndrome, failed back surgery, sciatica, spinal stenosis, shingles and other maladies."

The non-invasive Calmare pain therapy device uses the biophysical "Scrambler Therapy" technology, which was developed in Italy by CTT's client, Professor Giuseppe Marineo. CTT's partner, GEOMC Co. Ltd. of Seoul, Korea is manufacturing the Calmare device, which has U.S. FDA clearance and European Union CE Mark clearance for sales. For more information about Calmare Pain Therapy Treatment, visit www.calmarett.com.